AACR 2023

AACR 2023 Highlights Novel Research in NSCLC and ES-SCLC

Research presented at AACR 2023 highlighted a potential new standard of care for NSCLC and other novel treatments for NSCLC and ES-SCLC.

Doctor and cancer patient looking at a computer

Camonsertib-PARP Inhibitor Combos May Meet Unmet Need in Advanced Solid Tumors

Combining camonsertib with PARP inhibitors may be an effective strategy for treating advanced solid tumors, a study suggests.

Alectinib approved for non-small cell lung cancer.

Surufatinib Plus Toripalimab Deemed Potential First-Line Option for NSCLC

First-line treatment with surufatinib and toripalimab provided disease control in 100% of patients with advanced, PD-L1+ NSCLC.

Salmonella-IL2 May Improve Upon FOLFIRINOX in Stage IV Pancreatic Cancer

Salmonella-IL2 plus FOLFIRINOX may be more effective than FOLFIRINOX alone in patients with stage IV pancreatic cancer, a phase 2 study suggests.

MEDI1191 Plus Durvalumab Appears Safe, Active in Advanced Solid Tumors

Combination treatment with MEDI1191 and durvalumab has demonstrated activity in a phase 1 trial of patients with advanced solid tumors.

ALLO-316, a CAR T-Cell Therapy, Shows Activity in Advanced RCC

ALLO-316 has shown activity in a phase 1 study of patients with heavily pretreated, advanced clear cell renal cell carcinoma.

Bispecific CAR T-Cell Therapy Has “Robust” Activity in Non-Hodgkin Lymphoma

A bispecific CAR T-cell therapy produced responses in 91% of patients with relapsed/refractory non-Hodgkin lymphoma in a phase 1 trial.

AFM13 Proves Active in Relapsed/Refractory PTCL, Especially AITL

The bispecific antibody AFM13 elicits responses in patients with relapsed/refractory peripheral T-cell lymphoma, a phase 2 study suggests.

Petosemtamab Shows “Clinically Meaningful Activity” in Advanced HNSCC

Petosemtamab can produce durable responses in patients with advanced head and neck squamous cell carcinoma, a phase 1/2 study suggests.

Hereditary Cancer Syndromes Often Missed Under Current Screening Guidelines

Following genetic screening guidelines may cause clinicians to miss as many as 40% of patients with high-risk hereditary cancer syndromes, a study suggests.

REGN5459 Produces Durable Responses in Relapsed/Refractory Multiple Myeloma

REGN5459 appears safe and can produce durable responses in patients with relapsed or refractory multiple myeloma, a phase 1/2 study suggests.

Neoadjuvant Vibostolimab Plus Pembrolizumab Demonstrates Activity in Melanoma

Neoadjuvant vibostolimab plus pembrolizumab has shown antitumor activity in a phase 1/2 trial of patients with stage IIIB-D melanoma.

Results With Atezolizumab and Bevacizumab May Prove Practice-Changing for HCC

Adjuvant treatment with atezolizumab and bevacizumab prolongs recurrence-free survival, when compared with active surveillance, in patients with hepatocellular carcinoma, a phase 3 study suggests.

Risk of Drug-Drug Interactions in Patients With HIV and Cancer

As many as 1 in 4 patients receiving treatment for cancer and HIV may be at risk of experiencing drug-drug interactions, according to researchers.

Pegargiminase Prolongs PFS, OS in Nonepithelioid Pleural Mesothelioma

Adding pegargiminase to standard frontline chemotherapy improves outcomes in patients with nonepithelioid pleural mesothelioma, a phase 2/3 study suggests.

Perioperative Durvalumab Improves Outcomes in Resectable NSCLC

Results from the AEGEAN trial suggest that adding perioperative durvalumab to neoadjuvant chemotherapy can improve outcomes in patients with resectable NSCLC.